Abattis Unveils “Comfort”, Its Proprietary New Chronic Pain and Inflammation Product to Start Shipping November 2018

VANCOUVER, British Columbia, Sept. 24, 2018 (GLOBE NEWSWIRE) — Abattis Bioceuticals Corp. (the “Company” or “Abattis”) (CSE:ATT) (OTC:ATTBF) is pleased to announce the pending release of “Comfort”, a nutraceutical designed to target chronic pain and inflammation. As previously announced, the Company hopes to launch Comfort on Cyber Monday through the Company’s wholly-owned subsidiary, Vergence Naturals Ltd.

“According to a report from the Industry of Medicine, more than 100 million people in North America suffer from chronic pain and inflammation¹,” stated Rob Abenante, Abattis President and CEO.  “That same report estimates the pain-price tag for medical treatments and lost productivity at more than $600 billion annually¹, making chronic pain and inflammation major drains on the economy. With Comfort, we hope to address a severely disabling condition that affects a large proportion of our population.”

The Nielsen Company states market size for over-the-counter pain relief grew from $3.7 billion in 2014 to $4.2 billion in 2017². At the same time, the number of deaths associated with nonsteroidal anti-inflammatory drugs (“NSAIDs”) and opioids, as reported by the United States Centers for Disease Control and Prevention, has also grown. Clearly, there is an urgent need for effective and safe solutions to address the growing problem of chronic pain and inflammation.

A photo accompanying this announcement is available at http://www.globenewswire.com/NewsRoom/AttachmentNg/e5b472f2-e983-4e60-98bc-cb1ad92b0ebb

Dr. Brazos Minshew, MSc, ND and President of the Abattis Medical Advisory Board, explains, “Chronic pain occurs when internal systems within our body break down and fail to produce important endogenous chemicals. One of our body’s key pain management systems works through the production of bioactive lipids known as endocannabinoids which bind to and activate the CB-1 and CB-2 cannabinoid receptors. When activated, CB-1 and CB-2 modulate neural activity, helping our bodies cope with pain without being overwhelmed. Our body’s other principal pain management system works through the production of endorphins that interact with opiate receptors to reduce our perception of pain.

When our bodies experience pain that is too severe or lasts too long, our ability to produce endocannabinoids and endorphins slows and eventually exhausts, and we join the millions of people disabled or impaired by chronic pain.”

Comfort, our new proprietary nutraceutical, which contains Alpinia Galangal and Capsicum Annuum was developed by Abattis scientists to activate the endocannabinoid system and nourish endorphin release in response to chronic pain. Comfort will be manufactured in accordance with Canadian Natural Health Products (NHP) monographs and under the US Food and Drug Administration’s (FDA) Current Good Manufacturing Practice (CGMP) regulations. Comfort  is scheduled for public release on Cyber Monday, being November 26, 2018.

“Rob Abenante”
Robert Abenante, President & CEO

About Abattis Bioceuticals Corp.

Abattis is a leading diversified cannabis company, with interests in operations engaged in growing, extraction, testing, propagation and retail distribution. Over the past year, Abattis has made key acquisitions to leverage synergies and vertically integrate its business. Through its partnership with Northern Vine Labs and its investment in XLABS Therapeutics (ONT) Inc., Abattis has access to a fully licenced laboratory facility and an industrial size laboratory currently in the process of obtaining a Health Canada dealer’s license and, through its wholly owned subsidiary Gabriola Green Farms, it has applied for a Health Canada license to produce and sell Cannabis flower and oils. Abattis also operates a retail vaporizers business through its wholly owned subsidiary, Green Tree Therapeutics, which offers 10 unique branded SKUs online and across the country and owns a series of marketing, licensing and technology rights. Abattis has also partnered with a number of organizations, including the University of British Columbia Faculty of Land and Food Systems, with which it is developing delivery platforms with increased stability and bioavailability for cannabinoid rich THC-free hemp extracts. For more information, visit the Company’s website at: www.abattis.com

Sources

1 – https://www.webmd.com/pain-management/news/20110629/100-million-americans-have-chronic-pain

2 – https://www.chpa.org/otcscategory.aspx

For inquiries please contact (808) 650-3007 or at investors@abattis.com. Abattis inquiries are managed by Canada One Communications Inc.

About Canada One Communications Inc.

Canada One is a full-service Investor Relations and Marketing company that focuses on both private and public sectors within the Canadian markets. Canada One offers timely responses to all investor inquiries over several mediums and effective, thorough market awareness programs that are specifically designed to maximize exposure and bring value to shareholders. Canada One’s dedicated and experienced team strives to promote client information to the public and educate potential investors on the various developments of its clients. From basic phone-call and email investor correspondence, to full-scale comprehensive marketing packages which includes industry analysis, website development, corporate videos and other marketing programs, Canada One provides a full suite of services that are fully compliant with Canadian securities regulations. Canada One is driven by an uncompromising dedication to provide publicly listed and private companies with across-the-board investor relations and marketing solutions, directly translating these services into organic growth and increased market value of its valued clients.

NEITHER THE CANADIAN SECURITIES EXCHANGE NOR ITS REGULATIONS SERVICES PROVIDER HAS REVIEWED OR ACCEPTS RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.

This press release contains forward-looking statements. The use of any of the words “anticipate”, “continue”, “estimate”, “expect”, “may”, “will”, “project”, “intends”, “should”, “believe” and similar expressions are intended to identify forward-looking statements. Forward-looking statements in this press release include statements regarding: the Company’s plan to launch Comfort on Cyber Monday; the expected benefits of Comfort; and the statement that Comfort will be manufactured in accordance with NHP monographs and under the CGMP regulations. Although the Company believes that the expectations and assumptions on which the forward-looking statements are based are reasonable, undue reliance should not be placed on the forward-looking statements because the Company can give no assurance that they will prove to be correct. Since forward-looking statements address future events and conditions, by their very nature they involve inherent risks and uncertainties, including: that the Company will not launch Comfort on Cyber Monday; that Comfort will not benefit users as expected; that Comfort will not be manufactured in accordance with NHP monographs or under CGMP regulations; that the Company will not be able to execute its proposed business plan in the time required or at all due to regulatory, financial or other issues; that the Company’s competitors may develop competing technologies; changes in regulatory requirements; and other factors beyond the Company’s control. Additional risk factors are included in the Company’s Management’s Discussion and Analysis, available under the Company’s profile on www.sedar.com. The forward-looking statements are made as at the date hereof and the Company disclaims any intent or obligation to publicly update any forward-looking statements, where because of new information, future events or results, or otherwise, except as required by applicable securities laws.